Aeglea BioTherapeutics, a biotechnology company, agreed to acquire Spyre Therapeutics, a biotechnology research firm, in a $110m deal. "Our management and our Board of Directors thoroughly explored numerous strategic alternatives and believe this acquisition of Spyre provides a phenomenal outcome for our stockholders. Spyre's approach to therapeutics development aims to transform the current treatment experience for individuals living with IBD. The company is making rapid progress advancing their two parallel lead programs into the clinic, and we believe these programs will enable us to capture a sizable share of the growing IBD market," Jonathan D. Alspaugh, Aeglea President and Chief Financial Officer.